Herbal drugs and drug interactions

Year 2012, Volume: 16 Issue: 1, 9 - 22, 07.03.2014

Gül Dülger

Abstract

Keywords

StJohn’s wort, garlic, ginkgo, ginger, ginseng

References

• Bent S, Ko R. Commonly used herbal medicines in the United States: A review. Am J Med 2004; 116: 478-485.
• Stein K. Herbal supplements and prescription drugs. J Amer Dietetic Ass 2000; 100: 412.
• Graham RE, Gandhi TK, Borus J, Seger AC, Burdick E, Bates DW, Phillips RS, Weingart SN. Risk of concurrent use of prescription drugs with herbal and dietary sup- plements in ambulatory care. In: Advances in Patient Safety: New Directions and Alternative Approaches Vol. 4: Technology and Medication Safety. editors: Henriksen K, Battles JB, Keyes MA, Grady ML. Rock- ville (MD): Agency for Healthcare Research and Qual- ity (US), 2008.
• Tachjian A, Maria V, Jahangir A. Use of herbal products and potential interactions in patients with cardiovascu- lar diseases. J Amer Coll Cardiol 2010; 55: 515-25.
• Mohamed-Eslam FM, Frye RF. Effect of herbal supple- ments on drug glukuronidation. Review of clinical, ani- mal, and iv vitro studies. Planta Med 2011; 77: 311-21.
• Gonzales-Stuart A. Herbal product use by older adults. Maturitas 2011; 68: 52-5.
• Izzo A, Ernst E. Interactions Between Herbal Medicines and Prescribed Drugs. Drugs 2009; 69: 1777-98.
• Messina BAM. Herbal supplements: Facts and Myths- Talking to your patients about herbal supplements. J PeriAnesthesia Nursing 2006; 21: 268-78.
• Saw JT, Bahari MB, Ang HH, Lim YH. Potential drug- herb interaction with antiplatelet/anticoagulant drugs. Complement Ther Clin Pract 2006; 12: 236-41.
• Mehta DH, Gardiner PM, Phillips RS, McCarthy EP. Herbal and dietary supplement. Disclosure to health care providers by individuals with chronic conditions. J Altern Complement Med 2008; 14: 1263-69.
• Ang-Lee MK, Moss J, Yuan CS. Herbal medicines and perioperative care. JAMA 2011; 286: 208-16.
• Colalto C. Herbal Interactions on absorption of drugs: Mechanism of action and clinical risk assessment. Phar- macol Res 2010; 62: 207-27.
• Valli G, Giardina EG. Benefits, adverse effects and drug interactions of herbal therapies with cardiovascular ef- fects. J Amer Coll Cardiol 2002; 39: 1083-95.
• Izzo AA, Di Carlo G, Borrelli F, Ernst E. Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction. Int J Cardiol 2005; 98: 1-14.
• Niggemann B, Grüber C. Side effects of complementary and alternative medicine. Allergy 2003; 58: 707-16.
• Hafner-Blumenstiel V. Herbal drug-drug interaction and adverse drug reactions. Ther Umsch 2011; 68: 54-7.
• Zhou S, Zhou Z, Li C, X. Chen X, Yu X, Xue C, Hering- ton A. Identification of drugs that interact with herbs in drug development. Drug Discovery Today 2007; 12: 664-73.
• Zhou S, Gao Y, Jiang W, Huang M, Xu A, Paxton JW. Interactions of herbs with cytochrome P450. Drug Metab Rev 2003; 35: 35-98.
• Zhou S, Lim LY, Chowbay B. Herbal modulation of P- glycoprotein. Drug Metab Rev 2004; 36: 57-104.
• Miller LG. Herbal medicinals: selected clinical consider- ations focusing on known or potential drug-herb interac- tions. Arch Intern Med 1998; 158: 2200-11.
• Hu Z, Yang X, Ho PC, Chan SY, Heng PW, Chan E, Duan W, Koh HL, Zhou S. Herb-drug interactions: a literature review. Drugs 2005; 65: 1239-82.
• Huang SM, Lesko LJ..Drug-Drug, Drug–Dietary Supple- ment, and Drug–Citrus Fruit and Other Food Interac- tions: What Have We Learned? J Clin Pharmacol 2004; 44: 559-69.
• Tarirai C, Viljoen AM, Hamman JH. Herb-drug pharma- cokinetic interactions reviewed. Expert Opin Drug Me- tab Toxicol 2010; 6: 1515-38.
• Tirona RG, Bailey DG. Herbal product-drug interactions mediated by induction. Br J Clin Pharmacol 2006; 61: 677-81.
• Abebe W. Herbal medication: potential for adverse inter- actions with analgesic drugs. J Clinical Pharmacy Therap 2002; 27: 391-401.
• Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gen- try WB, Cui Y, Ang CY. Clinical assessment of effects of botanical supplementation on cytochrome P450 pheno- types in the elderly: St John’s wort, garlic oil, Panax gin- seng and Ginkgo biloba. Drugs Aging 2005; 22: 525-39.
• Gurley BJ, Swain A, Williams DK, Barone G, Battu SK. Gauging the clinical significance of P-glycoprotein-me- diated herb-drug interactions: comparative effects of St.John’s wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. Mol Nutr Food Res 2008; 52: 772-9.
• Chen XW, Serag ES, Sneed KB, Liang J, Chew H, Pan SY, Zhou SF. Clinical Herbal Interactions with Conventional Drugs: From Molecules to Maladies. Curr Med Chem 2011 [In press].
• Asdaq SM, Inamdar MN, Asad M. Effect of conventional antihypertensive drugs on hypolipidemic action of gar- lic in rats. Indian J Exp Biol 2009; 47: 176-81.
• Asdaq SM, Inamdar MN. Pharmacodynamic interaction of captopril with garlic in isoproterenol-induced myo- cardial damage in rat. Phytother Res 2010; 24: 720-5.
• Asdaq SM, Inamdar MN. Potential of garlic and its ac- tive constituent, S-allyl cysteine, as antihypertensive and cardioprotective in presence of captopril. Phytomedicine 2010; 17: 1016-26.
• Asdaq SM, Inamdar MN. The potential for interaction of hydrochlorothiazide with garlic in rats.Chem Biol Inter- act 2009; 181: 472-9.
• Mousa SA. Antithrombotic effects of naturally derived products on coagulation and platelet function. Methods Mol Biol 2010; 663: 229-40.
• Yang AK, He SM, Liu L, Liu JP, Wei MQ, Zhou SF. Herb- al interactions with anticancer drugs: mechanistic and clinical considerations. Curr Med Chem 2010; 17: 1635- 78.
• Hajda J, Rentsch KM, Gubler C, Steinert H, Stieger B, Fat- tinger K. Garlic extract induces intestinal P-glycoprotein, but exhibits no effect on intestinal and hepatic CYP3A4 in humans. Eur J Pharm Sci 2010; 41: 729-35.
• Berginc K, Trdan T, Trontelj J, Kristl A. HIV protease in- hibitors: garlic supplements and first-pass intestinal me- tabolism impact on the therapeutic efficacy. Biopharm Drug Dispos 2010; 31: 495-505.
• Berginc K, Trontelj J, Kristl A. The influence of aged gar- lic extract on the uptake of saquinavir and darunavir into HepG2 cells and rat liver slices. Drug Metab Pharmacok- inet 2010; 25: 307-13.38.
• Dostalek M, Pistovcakova J, Jurica J, Tomandl J, Linhart I, Sulcová A, Hadasova E. Effect of St John’s wort (Hy- pericum perforatum) on cytochrome P-450 activity in perfused rat liver. Life Sci 2005; 78: 239-44.
• Di YM, Li CG, Xue CC, Zhou SF. Clinical drugs that in- teract with St. John’s wort and implication in drug devel- opment. Curr Pharm Des 2008; 14: 1723-42.
• Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit- Singh CJ, Willson TM, Collins JL, Kliewer SA. St. John’s wort induces hepatic drug metabolism through activa- tion of the pregnane X receptor. Proc Natl Acad Sci USA 2000; 97: 7500-2.
• Dürr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Stein- ert HC, Meier PJ, Fattinger K. St John’s Wort induces intestinal P-glycoprotein/MDR1 and intestinal and he- patic CYP3A4. Clin Pharmacol Ther 2000; 68: 598-604.
• Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD. The effects of St John’s wort (Hypericum per- foratum) on human cytochrome P450 activity.Clin Phar- macol Ther 2001; 70: 317-26.
• Markowitz JS, DeVane CL.The emerging recognition of herb-drug interactions with a focus on St. John’s wort (Hypericum perforatum). Psychopharmacol Bull 2001; 35: 53-64.
• Markowitz JS, Donovan JL, De Vane CL, Robin MT, Ruan Y, Wang J-S, Chavin KD. Effect of St John’s wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003; 290: 1500-4.
• Kliewer SA. The Nuclear Pregnane X Receptor Regulates Xenobiotic Detoxification. J Nutr 2003; 133: 2444S-7S.
• Staudinger JL, Ding X, Lichti K. Pregnane X receptor and natural products: beyond drug-drug interactions. Expert Opin Drug Metab Toxicol 2006; 2: 847-57.
• Kim S, Dinchuk JE, Anthony MN, Orcutt T, Zoeckler ME, Sauer MB, Mosure KW, Vuppugalla R, Grace JE Jr, Simmermacher J, Dulac HA, Pizzano J, Sinz M. Evalua- tion of Cynomolgus Monkey Pregnane X Receptor, Pri- mary Hepatocyte, and in Vivo Pharmacokinetic Changes in Predicting Human CYP3A4 induction. Drug Metab Dispos 2010; 38: 16–24.
• Mannel M. Drug interactions with St John’s wort: mecha- nisms and clinical implications. Drug Saf 2004; 27: 773-97.
• Choudhuri S, Valerio LG Jr. Usefulness of studies on the molecular mechanism of action of herbals/botanicals: The case of St. John’s wort. J Biochem Mol Toxicol 2005; 19: 1-11.
• Komoroski BJ, Zhang S, Cai H, Hutzler JM, Frye R, Tracy TS, Strom SC, Lehmann T, Ang CY, Cui YY, Venkatara- manan R. Induction and inhibition of cytochromes P450 by the St. John’s wort constituent hyperforin in human hepatocyte cultures. Drug Metab Dispos 2004; 32: 512-8.
• Gutmann H, Poller B, Büter KB, Pfrunder A, Schaffner W, Drewe J. Hypericum perforatum: which constituents may induce intestinal MDR1 and CYP3A4 mRNA ex- pression? Planta Med 2006;72: 685-90.
• Borrelli F, Izzo AA. Herb–Drug Interactions with St John’s Wort (Hypericum perforatum): an Update on Clinical Observations. AAPS J 2009; 11: 710-27.
• Hall SD,Wang Z, Huang SM, Hamman MA, Vasavada N, Adigun AQ, Hilligoss JK, Miller M, Gorski JC. The interaction between St John’s wort and an oral contra- ceptive. Clin Pharmacol Ther 2003; 74: 525-35.
• Andrén L, Andreasson Å, Eggertsen R. Interaction be- tween a commercially available St. John’s wort product (Movina) and atorvastatin in patients with hypercholes- terolemia Eur J Clin Pharmacol 2007; 63: 913–6
• Zhou S, Chan E, Pan SQ, Huang M, Lee EJ. Pharmacoki- netic interactions of drugs with St John’s wort. Psychop- harmacol 2004; 18: 262-76.
• Qi JW, Nakamura K, Hosokawa S, Okada Y, Horiuchi R, Yamamoto K. Time-dependent induction of midazolam- 1-hydroxylation enzymes in rats treated with St. John’s wort. Biol Pharm Bull 2005; 28: 1467-71.
• Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ. Effect of St John’s wort and ginseng on the pharmacokinetics and phar- macodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 2004; 57: 592-9.
• Mai I, Bauer S, Perloff ES, Johne A, Uehleke B, Frank B, Budde K, Roots I. Hyperforin content determines the magnitude of the St John’s wort-cyclosporine drug inter- action. Clin Pharmacol Ther 2004; 76: 330-40.
• Wang Z, M. Hamman, S. Huang, L. J. Lesko, S. D. Hall. Effect of St John’s wort on the pharmacokinetics of fex- ofenadine. Clin Pharmacol Ther 2002; 71: 414-20.
• He SM, Yang AK, Li XT, Du YM, Zhou SF. Effects of herbal products on the metabolism and transport of anti- cancer agents. Expert Opin Drug Metab Toxicol 2010; 6: 1195-213.
• Komoroski BJ, Parise RA, Egorin MJ, Strom SC, Venka- taramanan R. Effect of the St. John’s wort constituent hy- perforin on docetaxel metabolism by human hepatocyte cultures. Clin Cancer Res 2005; 11: 6972-9.
• Vlachojannis J, Cameron M, Chrubasik S. Drug interac- tions with St John’s wort. Pharmacol Res 2011; 63: 254-56.
• Imai H, Kotegawa T, Tsutsumi K, Morimoto T, Eshima N, Nakano S, Ohashi K.The recovery time-course of CYP3A after induction by St John’s wort administration. Br J Clin Pharmacol 2008; 65: 701-7.
• Hellum BH, Hu Z, Nilsen OG.Trade herbal products and induction of CYP2C19 and CYP2E1 in cultured human hepatocytes. Basic Clin Pharmacol Toxicol 2009; 105: 58- 63.
• Mueller SC, Majcher-Peszynska J, Uehleke B, Klammt S, Mundkowski RG, W Miekisch W, Sievers H, Bauer S, Frank B, Kundt G, Drewelo B. The extent of induction of CYP3A by St. John’s wort varies among products and is linked to hyperforin dose. Eur J Clin Pharmacol 2006; 62: 29–36.
• Mueller SC, Majcher-Peszynska J, Mundkowski RG, Uehleke B, Klammt S, Sievers H Lehnfeld R, Frank B, Thurow K, Kundt G, Drewelow B. No clinically relevant CYP3A induction after St. John’s wort with low hyper- forin content in healthy volunteers. Eur J Clin Pharmacol 2009; 65: 81–7.
• Arold G, Donath F, Maurer A, Diefenbach K, Bauer S, Henneicke-von Zepelin HH, Friede M, Roots I.No rel- evant interaction with alprazolam, caffeine, tolbuta- mide, and digoxin by treatment with a low-hyperforin St John’s wort extract. Planta Med 2005; 71: 331-7.
• Madabushi R, Frank B, Drewelow B, Derendorf H, But- terweck V. Hyperforin in St. John’s wort drug interac- tions. Eur J Clin Pharmacol 2006; 62: 225-33.
• Gödtel-Armbrust U, Metzger A, Kroll U, Kelber O, Wo- jnowski L. Variability in PXR-mediated induction of CYP3A4 by commercial preparations and dry extracts of St. John’s wort. Naunyn Schmiedebergs Arch Pharmacol 2007; 375:377-82.
• Majcher-Peszynska J, Mundkowski RG, Uehleke B, Klam- mt S, Sievers H, Lehnfeld R, Frank B, Thurow K, Kundt G, Drewelow B. No clinically relevant CYP3A induction af- ter St. John’s wort with low hyperforin content in healthy volunteers. Eur J Clin Pharmacol 2009; 65: 81-7.
• Komoroski BJ, Zhang S, Cai H, Hutzler JM, Frye R, Tracy TS, Strom SC, Lehmann T, Ang CY, Cui YY, Venkatara- manan R. Induction and inhibition of cytochromes P450 by the St. John’s wort constituent hyperforin in human hepatocyte cultures. Drug Metab Dispos 2004; 32: 512-8.
• Rahmioglu N, Heaton J, Clement G, Gill R, Surdulescu G, Zlobecka K, Hodgkiss D, Ma Y, Hider RC, Smith NW, Ahmadi KR.Genetic epidemiology of induced CYP3A4 activity. Pharmacogenet Genomics 2011; 21: 642-51.
• Schellander R, Donnerer J. Antidepressants: clinically relevant drug interactions to be considered. Pharmacol- ogy. 2010; 86: 203-15.
• Chiang HM, Chao PD, Hsiu SL, Wen KC, Tsai SY, Hou YC Ginger significantly decreased the oral bioavailabil- ity of cyclosporine in rats. Am J Chin Med 2006; 34: 845- 55.
• Koo KL, Ammit AJ, Tran VH, Duke CC, Roufogalis BD.Gingerols and related analogues inhibit arachidonic acid-induced human platelet serotonin release and ag- gregation. Thromb Res 2001; 103: 387-97.
• Verma SK, Bordia A. Ginger, fat and fibrinolysis. Indian J Med Sci 2001; 55: 83-6.
• Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ Effect of ginkgo and ginger on the pharmacokinetics and pharmacody- namics of warfarin in healthy subjects. Br J Clin Pharma- col 2005; 59: 425-32.
• Krüth P, Brosi E, Fux R, Mörike K, Gleiter CH. Ginger-as- sociated over anticoagulation by phenprocoumon. Ann Pharmacother 2004; 38: 257-60.
• Lesho EP, Saullo L, Udvari-Nagy SA 76-year-old woman with erratic anticoagulation. Cleve Clin J Med 2004; 71: 651-6.
• Young HY, Liao JC, Chang YS, Luo YL, Lu MC, Peng WH.Synergistic effect of ginger and nifedipine on hu- man platelet aggregation: a study in hypertensive pa- tients and normal volunteers. Am J Chin Med 2006; 34: 545-51.
• Shalansky S, Lynd L, Richardson K, Ingaszewski A, Kerr CRisk of warfarin-related bleeding events and supra- therapeutic international normalized ratios associated with complementary and alternative medicine: a longi- tudinal analysis. Pharmacotherapy 2007; 27: 1237-47.
• Ali BH, Blunden G, Tanira MO, Nemmar A. Some phyto- chemical, pharmacological and toxicological properties of ginger (Zingiber officinale Roscoe): A review of recent research. Food Cheml Toxicol 2008;46: 409-20.
• Heeba GH, Abd-Elghany MI. Effect of combined ad- ministration of ginger (Zingiber officinale Roscoe) and atorvastatin on the liver of rats.Phytomedicine 2010; 17: 1076-81.
• Kudolo GB, Dorseya S, Blodgett J. Effect of the ingestion of Ginkgo biloba extract on platelet aggregation and uri- nary prostanoid excretion in healthy and Type 2 diabetic subjects. Thrombosis Research 2003; 108: 151–60.
• Jayasekera N, Moghal A, Kashif F. Herbal medicines and postoperative haemorrhage. Anesthesia 2005; 60: 712-13.
• Gold JL, Laxer DA, Dergal JM, Lanctot KL, Paula A. Rochon PA. Herbal-drug therapy interactions: A focus on dementia. Curr Opin Clin Nutr Metab Care 2001; 4: 29-34.
• Bebbington A, Kulkarni R, Roberts P.Ginkgo biloba: per- sistent bleeding after total hip arthroplasty caused by herbal self-medication. J Arthroplasty 2005; 20:125-6.
• Fessenden JM, Wittenborn W, Clarke L. Gingko biloba: a case report of herbal medicine and bleeding postop- eratively from a laparoscopic cholecystectomy. Am Surg 2001; 67: 33-5.
• Haller CA, Meier KH, Olson KR. Seizures reported in as- sociation with use of dietary supplements. Clin Toxicol (Phila) 2005; 43: 23-30.
• Kim YS, Pyo MK, Park KM, Park PH, Hahn BS, Wu SJ, Yun-Choi HS. Antiplatelet and antithrombotic effects of a combination of ticlopidine and ginkgo biloba ext (EGb 761). Thromb Res 1998; 91: 33-8.
• Kim BH,Kim KP, Lim KS, Kim JR, Yoon SH, Cho JY, Lee YO, Lee KH, Jang IJ, Shin SG, Yu KS. Influence of Gink- go biloba extract on the pharmacodynamic effects and pharmacokinetic properties of ticlopidine: an open-label, randomized, two-period, two-treatment, two-sequence, single-dose crossover study in healthy Korean male vol- unteers. Clin Ther 2010; 32: 380-90.
• Aruna D, Naidu MUPharmacodynamic interaction stud- ies of Ginkgo biloba with cilostazol and clopidogrel in healthy human subjects. Br J Clin Pharmacol 2007; 63: 333-8.
• Ryu KH, Han HY, Lee SY, Jeon SD, Im GJ, Lee BY, Kim K, Lim KM, Chung JH. Ginkgo biloba extract enhances antiplatelet and antithrombotic effects of cilostazol with- out prolongation of bleeding time.Thromb Res 2009; 124: 328-3.
• Jiang X, Blair EY, McLachlan AJ. Investigation of the effects of herbal medicines on warfarin response in healthy subjects: a population pharmacokinetic-phar- macodynamic modeling approach. J Clin Pharmacol 2006; 46: 1370-8.
• Wolf HR. Does Ginkgo biloba special extract EGb 761 provide additional effects on coagulation and bleeding when added to acetylsalicylic acid 500 mg daily? Drugs RD 2006; 7:163-72.
• Beckert BW, Concannon MJ, Henry SL, Smith DS, Puck- ett CL.The effect of herbal medicines on platelet func- tion: an in vivo experiment and review of the literature. Plast Reconstr Surg 2007; 120: 2044-50.
• Bone KM. Potential interaction of Ginkgo biloba leaf with antiplatelet or anticoagulant drugs: what is the evi- dence? Mol Nutr Food Res 2008; 52: 764-71.
• Fan L, Tao GY, Wang G, Chen Y, Zhang W, He YJ, Li Q, Lei HP, Jiang F, Hu DL, Huang YF, Zhou HH.Effects of Ginkgo biloba extract ingestion on the pharmacokinetics of talinolol in healthy Chinese volunteers. Ann Pharma- cother 2009; 43: 944-9.
• Berecz R, Dorado P, De La Rubia A, Cáceres MC, De- grell I, LLerena A.The role of cytochrome P450 enzymes in the metabolism of risperidone and its clinical rele- vance for drug interactions. Curr Drug Targets 2004; 5: 573-9.
• Yeung EYH, Sueyoshi T, Negishi M, Chang TKH. Identi- fication of Ginkgo biloba as a novel activator of pregnane X receptor. Drug Metab dispos 2008; 36: 2270-6.
• Hellum BH, Nilsen OG. In vitro inhibition of CYP3A4 metabolism and P-glycoprotein-mediated transport by trade herbal products. Basic Clin Pharmacol Toxicol 2008; 102: 466-75.
• Hellum BH, Hu Z, Nilsen OG. The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes. Basic Clin Phar- macol Toxicol 2007; 100: 23-30.
• Sugiyama T, Kubota Y, Shinozuka K, Yamada S, Wu J, Umegaki KGinkgo biloba extract modifies hypoglycemic action of tolbutamide via hepatic cytochrome P450 medi- ated mechanism in aged rats.Life Sci 2004; 75: 1113-22.
• Uchida S,Yamada H, Li XD, Maruyama S, Ohmori Y, Oki T, Watanabe H, Umegaki K, Ohashi K, Yamada S. Effects of Ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers. J Clin Pharmacol 2006; 46: 1290-8.
• Zuo XC, Zhang BK, Jia SJ, Liu SK, Zhou LY, Li J, Zhang J, Dai LL, Chen BM, Yang GP, Yuan H. Effects of ginkgo biloba extracts on diazepam metabolism: a pharmacoki- netic study in healthy chinese male subjects. Eur J Clin Pharmacol 2010; 66: 503-9.
• Tang J, Sun J, Zhang Y, Li L, Cui F, He Z. Herb-drug interactions: Effect of Ginkgo biloba extract on the phar- macokinetics of theophylline in rats. Food Chem Toxicol 2007; 45: 2441-5.
• Taki Y, Yokotani K, Yamada S, Shinozuka K, Kubota Y, Watanabe Y, Umegaki K. Ginkgo biloba extract attenu- ates warfarin-mediated anticoagulation through induc- tion of hepatic cytochrome P450 enzymes by bilobalide in mice.Phytomedicine 2011 [In press].
• Yang CY, Chao PD, Hou YC, Tsai SY, Wen KC, Hsiu SL. Marked decrease of cyclosporin bioavailability caused by coadministration of ginkgo and onion in rats. Food Chem Toxicol 2006; 44: 1572-8.
• Yale SH, Glurich I. Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9. J Altern Complement Med 2005; 11: 433-9.
• Lin YY, Chu SJ, Tsai SH. Association Between Priapism and Concurrent Use of Risperidone and Ginkgo biloba. Mayo Clin Proc 2007; 82: 1288-91.
• Smolinske SC. Dietary supplement-drug interactions. J Am Med Womens Assoc 1999; 54: 191-2,195.
• Hao M, Ba Q, Yin J, Li J, Zhao Y, Wang H. Deglycosylat- ed Ginsenosides Are More Potent Inducers of CYP1A1, CYP1A2 and CYP3A4 Expression in HepG2 Cells than Glycosylated Ginsenosides. Drug Metab Pharmacokinet 2011; 26: 201-5.
• Lee SH, Ahn YM, Ahn SY, Doo HK, Lee BC. Interaction between warfarin and Panax ginseng in ischemic stroke patients. Altern Complement Med 2008; 14: 715-21.
• Bilgi N, Bell K, Ananthakrishnan AN. Atallah EImatinib and Panax ginseng: a potential interaction resulting in liver toxicity. Ann Pharmacother 2010; 44: 926-8.
• Gorshki JC, Huang S-M, A Pinto A, Hamman MA, Hilli- goss JK, Zaheer NA, Desai M, Miller M, Hall SD. The effect of echinacea (Echinace purpurea root) on cyto- chrome P450 activity in vivo. Clin Pharmacol Ther 2004; 75: 89-100.
• Mrozikiewicz PM, Bogacz A, Karasiewicz M, Mikolajc- zak PL, Ozarowski M, Seremak-Mrozikiewicz A, Czerny B, Bobkiewicz-Kozlowska T, Grzeskowiak E. The effect of standardized Echinacea purpurea extract on rat cyto- chrome P450 expression level.Phytomedicine 2010; 17: 830-3.
• Moltó J, Valle M, Miranda C, Cedeño S, Negredo E, Bar- banoj MJ, Clotet B. Herb-drug interaction between Echi- nacea purpurea and darunavir-ritonavir in HIV-infected patients.Antimicrob Agents Chemother 2011; 55: 326-30.
• Penzak SR, Robertson SM, Hunt JD, Chairez C, Malati CY, Alfaro RM, Stevenson JM, Kovacs JA. Echinacea purpurea significantly induces cytochrome P450 3A ac- tivity but does not alter lopinavir-ritonavir exposure in healthy subjects. Pharmacotherapy 2010; 30: 797-805.
• Hansen TS, Nilsen OG. Echinacea purpurea and P-glyc- oprotein drug transport in Caco-2 cells. Phytother Res 2009; 23: 86-91.
• Heinrich M, Modarai M, Kortenkamp A. Herbal extracts used for upper respiratory tract infections: are there clinically relevant interactions with the cytochrome P450 enzyme system? Planta Med 2008;74: 657-60.
• Freeman C, Spelman K. A critical evaluation of drug in- teractions with Echinacea spp. Mol Nutr Food Res 2008; 52: 789-98.
• Toselli F, Matthias A, Gillam EM. Echinacea metabolism and drug interactions: the case for standardization of a complementary medicine. Life Sci 2009; 85: 97-106.
• Chicca A, Raduner S, Pellati F, Strompen T, Altmann KH, Schoop R, Gertsch J. Synergistic immunomopharmaco- logical effects of N-alkylamides in Echinacea purpurea herbal extracts. Int Immunopharmacol 2009; 9: 850-8.
• Gold JL, Laxer DA, Dergal JM, Lanctot KL, Rochon PA. Herbal-Drug therapy interactions. Curr Opin Clin Nutr Metab Care 2001; 4: 29-34.
• Carrasco MC, Vallejo JR, Pardo-de-Santayana M, Peral D, Martín MA, Altimiras J. Interactions of Valeriana of- ficinalis L. and Passiflora incarnata L. in a patient treated with lorazepam. Phytother Res 2009; 23: 1795-6.
• Chaplin RL Jr, Jedynak J, Johnson D, Heiter D, Shovelton L, Garrett N. The effects of valerian on the time course of emergence from general anesthesia in Sprague-Dawley rats (Rattus norvegicus). AANA J 2007; 75: 431-5.
• Dalla Corte CL, Fachinetto R, Colle D, Pereira RP, Avila DS, Villarinho JG, Wagner C, Pereira ME, Nogueira CW, Soares FA, Rocha JB. Potentially adverse interactions between haloperidol and valerian. Food Chem Toxicol 2008; 46: 2369-75.
• Donovan JL, DeVane CL, Chavin KD, Wang JS, Gibson BB, Gefroh HA, Markowitz JS. Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers. Drug Metab Dispos 2004; 32: 1333-6.
• Hamann GL, Campbell JD, George CM. Warfarin-Cran- berry juice interaction. Ann Pharmacother 2011; 45:e17.
• Yap KY, See CS, Chan A. Clinically-relevant chemother- apy interactions with complementary and alternative medicines in patients with cancer. Recent Pat Food Nutr Agric 2010; 2: 12-55.